Today: 17 July 2026
Vodafone shares gain after Xavier Niel’s Vega seeks 19.87% voting stake
17 July 2026
1 min read

Vodafone shares gain after Xavier Niel’s Vega seeks 19.87% voting stake

LONDON, July 17, 2026, 10:07 BST — Market open. Trading on the London Stock Exchange begins at 08:00 and ends at 16:30.

  • Vodafone shares rose 3.2% to 120.01 pence at 09:28 BST.
  • Vega’s intended voting share rose to 19.87% from 17.13%.
  • Initial estimate suggests the increased exposure accounts for approximately 631 million shares, valued at around £757 million.

Shares of Vodafone Group Plc gained on Friday after investors weighed Vega Investment’s increased intended stake. The stock was at 120.01 pence as of 09:28 BST.

Following physical settlement, the Niel family vehicle anticipates holding 19.87% of voting rights, which is just 13 basis points under the 20% threshold.

This alters the investor question. Strategic influence has become more significant than a prompt takeover offer.

Vega reiterated that it has no plans to submit an offer. The company characterized its stake as a long-term, strategic minority investment.

MeasureJuly 10 agreementJuly 16 expected positionChange
Share capital16.21%18.80%2.59 points
Voting rights17.13%19.87%2.74 points
Referenced shares3.945 billionRoughly 4.576 billionRoughly 631 million
Value at 120.01pAbout £4.73 billionAbout £5.49 billionAbout £757 million*

Initial estimates are based on Vodafone’s reported voting denominator staying the same. Market values have been rounded.

Friday’s quote was 8.6% higher than the declared block price of 110.4792 pence. The 3.945 billion underlying shares had a value of approximately £4.73 billion.

This amounts to about £376 million more than the indicated £4.36 billion cash price. It does not represent a reported Vega profit.

Changes in financing expenses, derivative conditions and Vodafone’s last dividend may affect the deal’s economics. Vega has yet to reveal the price of the additional instrument.

On July 10, Vega reached a deal to purchase the stake from Emirates Telecommunications Group , also known as e&. Xavier Niel described Vodafone as “a compelling investment opportunity.” GlobeNewswire

NewStreet Research noted that Niel typically acquires stakes, retains them and aims to increase his influence. Berenberg commented that his entry might speed up cost reductions and boost cash flow growth.

Next up is the operating proof. Vodafone will release its first-quarter trading update on July 27.

Organic service revenue increased by 5.4% in fiscal 2026. Adjusted EBITDAaL was up 4.5% organically to €11.4 billion.

Chief Executive Margherita Della Valle described Vodafone as “a simpler company with better growth prospects.” Investors will be looking for those prospects to translate into cash. Vodafone

Vodafone forecasts fiscal 2027 EBITDAaL between €11.9 billion and €12.2 billion. Adjusted free cash flow is projected at €2.6 billion to €2.9 billion.

Germany is still the key variable. It contributed 37% of group EBITDAaL in fiscal 2026.

Vodafone has resolved a 19-month legal dispute with 62 ex-franchisees. Details of the agreement are confidential, and there was no acceptance of liability.

Risks: Regulatory approval and physical settlement are yet to be resolved. Germany’s recovery and the VodafoneThree integration continue to be execution challenges, and the cost of settling the franchise is not disclosed.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Iovance Jumps 10% as Market Eyes Amtagvi H2 Sales Forecast
    July 17, 2026, 7:58 AM EDT. Iovance Biotherapeutics (NASDAQ:IOVA) shares gained 10.2% between July 10 and 16, even as the SPDR S&P Biotech ETF and Nasdaq Biotechnology Index fell. The rally comes as investors turn attention to the company's second-half sales projection for Amtagvi, its flagship therapy, with projected quarterly revenue between $95.8 million and $105.8 million-a rise of 10.1% to 21.6% from the prior quarter's midpoint. With no material company news during the period, high trading volume and significant short interest highlight shifting market dynamics. Iovance's first quarter saw a 45% revenue lift thanks to Amtagvi, but the company also recorded a net loss of $79 million. Potential headwinds include patient health variables, manufacturing challenges affecting sales, and dilution risk from recent equity offerings.
GSK plc (LON:GSK) drops after cough medicine blow wipes £2.4 billion off market value
Previous Story

GSK plc (LON:GSK) drops after cough medicine blow wipes £2.4 billion off market value

Sensex Today: Nifty Tops 23,100 as IT Stocks Lift India Shares Ahead of RBI Decision
Next Story

India shares climb, with just five major stocks making up most Nifty gains

Go toTop